Aura Biosciences files Form 3 for director Bender

Aura Biosciences, Inc. filed an initial Form 3 for director Jeremy Bender.

Rhea-AI Filing Summary

Aura Biosciences, Inc. filed an initial Form 3 for director Jeremy Bender. This filing establishes his status as a reporting person but shows no reportable transactions, no current holdings entries, and no derivative positions, based on the zero counts in the transaction and derivative summaries.

Key Figures

Buy transactions: 0 transactions Sell transactions: 0 transactions Derivative transactions: 0 transactions +2 more

5 metrics

Buy transactions 0 transactions Transaction summary buyCount

Sell transactions 0 transactions Transaction summary sellCount

Derivative transactions 0 transactions derivativeTransactionCount in transactionSummary

Net buy/sell shares 0 shares netBuySellShares in transactionSummary

Holding entries 0 entries holdingEntries in transactionSummary

Key Terms

Form 3, reporting person, derivative positions

3 terms

Form 3 regulatory

"Aura Biosciences, Inc. filed an initial Form 3 for director"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reporting person regulatory

"This filing establishes his status as a reporting person"

derivative positions financial

"no derivative positions, based on the zero counts"

Derivative positions are contracts that derive their value from an underlying asset—such as a stock, bond, currency or commodity—and include instruments like options, futures and swaps. Think of them as bets or insurance tied to an asset’s future price: they let investors amplify returns, hedge risk or take exposure without owning the asset directly, which can meaningfully increase potential gains, losses and volatility in a portfolio.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Aura Biosciences (AURA) Form 3 for Jeremy Bender show?

The Form 3 for Jeremy Bender at Aura Biosciences establishes him as a director-level reporting person. It reports zero buy, sell, or derivative transactions and no current holdings entries, serving as a baseline ownership disclosure at the time of filing.

Are there any share purchases or sales reported in the AURA Form 3?

No transactions are reported. The transaction summary shows zero buy, zero sell, and netBuySellShares of 0, indicating no purchases, sales, or other reportable trades associated with this initial ownership statement.

Does the Aura Biosciences Form 3 disclose any derivative securities for Jeremy Bender?

No derivative positions are disclosed. The derivativeSummary is empty and the transaction summary lists derivativeTransactionCount of 0 and exerciseCount of 0, indicating no options, warrants, or similar instruments reported in this filing.

What role does Jeremy Bender hold at Aura Biosciences (AURA) in this Form 3?

The Form 3 identifies Jeremy Bender as a director of Aura Biosciences, Inc. He is not listed as an officer and is not marked as a ten percent owner, so his reporting status is tied specifically to his board position.

Does this Aura Biosciences Form 3 indicate any gifts or tax-related share withholdings?

No, the summary shows giftCount of 0 and taxWithholdingCount of 0. This means there are no reported gifts, no tax-withholding dispositions, and no restructuring-related share movements in this initial ownership filing for Jeremy Bender.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/08/2026 - 04:10 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Bender Jeremy

(Last) (First) (Middle)

C/O AURA BIOSCIENCES, INC.

80 GUEST STREET

(Street)

BOSTON MASSACHUSETTS 02135

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/07/2026

3. Issuer Name and Ticker or Trading Symbol
Aura Biosciences, Inc. [ AURA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24.1 - Power of Attorney.

No securities are beneficially owned.

	/s/ Conor Kilroy, as Attorney-in-Fact	07/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)